N-(tert-butyl)-2,2,2-triphenylacetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-(tert-butyl)-2,2,2-triphenylacetamide
• 英文别名: N-tert-butyl-2,2,2-triphenylacetamide
• 化学式: C₂₄H₂₅NO
• 分子量: 343.469
• InChiKey: OXKSSNDEOAPNMR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  三苯基乙酸 在 N,N-二异丙基乙胺 、 N,N,N′,N′-bis-tetramethylene-fluoro-formamidinium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 24.5h， 生成 N-(tert-butyl)-2,2,2-triphenylacetamide
  参考文献：
  名称：

  A protocol for amide bond formation with electron deficient amines and sterically hindered substrates

  摘要：

  已开发出一种酰氟体系偶联的方法，通过在高温下原位生成酰氟化合物并与胺发生反应，发现该方法对于难以偶联的底物和电子亏缺的胺具有高效率，而标准方法无法胜任。

  DOI：

  10.1039/c5ob02129d

文献信息

• Amine Activation:<i>N</i>-Arylamino Acid Amide Synthesis from Isothioureas and Amino Acids
  作者：Yan-Ping Zhu、Pieter Mampuys、Sergey Sergeyev、Steven Ballet、Bert U. W. Maes

  DOI：10.1002/adsc.201700134

  日期：2017.7.17

  functional group compatibility, with respect to side chain functionality of the amino acid (e. g. aliphatic and aromatic OH, (hetero)aromatic NH, amide NH, thioether), and the chiral amino acids do not undergo epimerization. The mechanism of the new amide synthesis has been studied.

  Ñ -arylamino酰胺已经通过基于新方法被合成ñ -芳基胺活化成异硫脲，随后用下铁催化氨基酸反应。可以使用三组分反应与市售试剂叔丁基异氰化物和S-苯基苯硫代磺酸盐轻松地制备活化的N-芳基胺。相对于氨基酸（例如脂族和芳族OH，（杂）芳族NH，酰胺NH，硫醚）的侧链官能度，该方案显示出广泛的官能团相容性，并且手性氨基酸不发生差向异构化。已经研究了新酰胺合成的机理。
• Synthesis and Identification of Small Molecules that Potently Induce Apoptosis in Melanoma Cells through G1 Cell Cycle Arrest
  作者：Robin S. Dothager、Karson S. Putt、Brittany J. Allen、Benjamin J. Leslie、Vitaliy Nesterenko、Paul J. Hergenrother

  DOI：10.1021/ja042913p

  日期：2005.6.1

  Late-stage malignant melanoma is a cancer that is refractory to current chemotherapeutic treatments. The average survival time for patients with such a diagnosis is 6 months. In general, the vast majority of anticancer drugs operate through induction of cell cycle arrest and cell death in either the DNA synthesis (S) or mitosis (M) phase of the cell cycle. Unfortunately, the same mechanisms that melanocytes possess to protect cells from DNA damage often confer resistance to drugs that derive their toxicity from S or M phase arrest. Described herein is the synthesis of a combinatorial library of potential proapoptotic agents and the subsequent identification of a class of small molecules (triphenyl methylamides, TPMAs) that arrest the growth of melanoma cells in the G1 phase of the cell cycle. Several of these TPMAs are quite potent inducers of apoptotic death in melanoma cell lines (IC50 similar to 0.5 mu M), and importantly, some TPMAs are comparatively nontoxic to normal cells isolated from the bone marrow of healthy donors. Furthermore, the TPMAs were found to dramatically reduce the level of active nuclear factor kappa-B (NF kappa B) in the cell; NF kappa B is known to be constitutively active in melanoma, and this activity is critical for the proliferation of melanoma cells and their evasion of apoptosis. Compounds that reduce the level of NF kappa B and arrest cells in the G1 phase of the cell cycle can provide insights into the biology of melanoma and may be effective antimelanoma agents.